Episode Details
Back to EpisodesThe Changing Landscape of Therapy in HER2-Low and Ultralow Breast Cancer (Part 1)
Episode 585
Published 8 months, 1 week ago
Description
Dr. Tiffany Traina and Dr. Josh Drago discuss the evolving treatment landscape for HER2-low and ultralow breast cancer, highlighting how pivotal trials like Destiny Breast-04 and Destiny Breast-06 have demonstrated significant efficacy improvements with trastuzumab deruxtecan while emphasizing the need to balance its toxicity profile with benefits for individual patients.